References
1. Tahara H. [Hypertension secondary to hyperparathyroidism] Nippon Rinsho. 2004 Mar;62 Suppl 3:517-20.
2. Abraham GE, Flechas JD, Hakala JC. Orthoiodosupplementation: Iodine sufficiency of the whole human body. Reproduced in Selected Clinical Studies and Literature Reviews, pp. xx.
3. Grineva EN, Malakhova TV, Tsoi UA, Smirnov BI. Efficacy of thyroxine and potassium iodide treatment of benign nodular thyroid lesions. Ter Arkh. 2003;75(8):72-75.
4. McDermott MT. Endocrine Secrets. Philadelphia, PA: Hanley and Belfus Inc, 1998.
5. Kelly GS. Peripheral metabolism of thyroid hormones: A review. Altern Med Rev. 2000 Aug;5(4):306-33.
6. Winterhoff H, Gumbinger HG, Vahlensieck U, Kemper FH, Schmitz H, Behnke B. Endocrine effects of Lycopus europaeus L. following oral application. Arzneimittelforschung. 1994 Jan;44(1):41-45.
7. White HL, Freeman LM, Mahony O, Graham PA, Hao Q, Court MH. Effect of dietary soy on serum thyroid hormone concentrations in healthy adult cats. Am J Vet Res. 2004 May;65(5):586-91.
8. Chandra AK, Mukhopadhyay S, Lahari D, Tripathy S. Goitrogenic content of Indian cyanogenic plant foods & their in vitro anti-thyroidal activity.Indian J Med Res. 2004 May;119(5):180-85.
9-20. Kelly GS. Peripheral metabolism of thyroid hormones: A review. Altern Med Rev. 2000 Aug;5(4):306-33. Reproduced in Selected Clinical Studies and Literature Reviews, pp. xx-xx.
21. Kohrle J, Spanka M, Irmscher K, Hesch RD. Flavonoid effects on transport, metabolism and action of thyroid hormones. Prog Clin Biol Res 1988;280:323-40.
22. Panda S, Kar A. Withania somnifera and Bauhinia purpurea in the regulation of circulating thyroid hormone concentrations in female mice. J Ethnopharmacol 1999;67:233-39.
23.Panda S, Kar A. Changes in thyroid hormone concentrations after administration of ashwagandha root extract to adult male mice. J Pharm Pharmacol 1998;50:1065-68.
24. Pohhloudek-Fabini R, Katterbach HA. On the presence of diiodotyrosine in Baltic Sea fucus. Pharmazie. 1965 Mar;20:176.
25. 2. Abraham GE, Flechas JD, Hakala JC. Orthoiodosupplementation: Iodine sufficiency of the whole human body. Reproduced in Selected Clinical Studies and Literature Reviews, pp. xx. Orthoiodosupplementation: Iodine sufficiency of the whole human body Guy. E. Abraham
26. Kelly GS. Peripheral metabolism of thyroid hormones: a review. Altern Med Rev. 2000 Aug;5(4):306-33. Reproduced in Selected Clinical Studies and Literature Reviews, pp. xx-xx.
27. Gartner R, Gasnier BC. Selenium in the treatment of autoimmune thyroiditis. Biofactors. 2003;19(3-4):165-70
28. Russell IJ. Neurochemical pathogeneses of fibromyalgia syndrome. Journal of Muscoskeletal Pain, 1996. 2(3):p.61-92.
29.Karkal S. Overcoming diagnostic and therapeutic obstacles in hypothyroidism. Emergency Medicine Reports, 1990. 11(23):219-27.
30. Lam KS. et al. Vasoactive intestinal peptide in the anterior pituitary is increased in hypothyroidism. Endocrinology 1989;124(2):1077-84.
31. Lam KS, et al. Vasoactive intestinal peptide in the anterior pituitary is increased in hypothyroidism. Endocrinology 1989;124(2):1077-84.
32. Kales A, et al. All night sleep studies in hypothyroid patients, before and after treatment. J Clin Endocrinol Metab 1967;27(11): 1593-99.
33. Eisinger J, Plantamura A, Ayavou T. Glycolysis abnormalities in fibromyalgia. J Am Coll Nutr 1994;13(2):144-48.
34. Fukuda K, et al. The chronic fatigue syndrome: A comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 1994;121(12):953-99.
35. Williams G, Pirmohamed J, Minors D, Waterhouse J, Buchan I, Arendt J, Edwards RH. Dissociation of body-temperature and melatonin secretion circadian rhythms in patients with chronic fatigue syndrome. Clin Physiol 1996;16(4):327-37.
36. Fukuda K, Ishhara K, Takeuchi T, Yamamoto Y, Inugami M. Core temperature pattern and self-rated lifestyle. Psychiatry Clin Neurosci 1998;52(2):243-45.
37. Shibui K, Okawa M, Uchiyama M, Ozaki S, Kamei Y, Hayakawa T, Urata J. Continuous measurement of temperature in non-24 hour sleep-wake syndrome. Psychiatry Clin Neurosci. 1998;52(2):236-37.
38. Title CR. Effects of triodothinoine in patients with metabolic insufficiency. JAMA 1956:162: 271.
39. Kurland GS, Hamolsky MW, Feedberg AS. Studies in non-myxedematous hypermetabolism: 1. The clinical syndrome and the effects of triiodothyronine, alone or combined with thyroxine. J. Clinical Endocrinology 1955:15:1354.
40. Sonkin LS. Myofascial pain due to metabolic disorders: Diagnosis and treatment. In: Myofascial Pain and Fibromyalgia: Trigger Point Management. Rachlin ES (ed.) St. Louis, MO: Mosby,1994:45-60.
41. McIntyre RS, et al. What to do if an initial antidepressant fails? Can Fam Physician 2003;49: 449-57.
42. Joffe, R.T., et al., Predictors of response to lithium and triiodothyronine augmentation of antidepressants in tricyclic non-responders. BrJPsychiatry, 1993. 163: p. 574-8.
43. Lowe J. Thyroid status of 38 fibromyalgia patients: Implications for the etiology of fibromyalgia. Clinical Bulletin Myofascial Ther. 1997;2(1):47-64.
44. Lowe J, et al. Effectiveness and safety of t3 therapy for euthyroid fibromyalgia: A double-blind placebo-controlled crossover study. Clinical Bulletin Myofascial Ther. 1997;294: 71-88.
45. Lowe JC, Reichman AJ, Yellin J. The process of change during T3 treatment for euthyroid fibromyalgia: A double-blind placebo-controlled crossover study. Clin. Bull. Myofascial Ther. 1997;2(2/3):91-124.
46.Lowe JC, Garrison RL, Reichman A, Yellin J. Triiodothyronine (T3) treatment of euthyroid fibromyalgia: A small-N replicaiton of a double-blind placebo-controlled crossover study. Clin. Bull. Myofascial Ther. 1997;2(4):71-88.
47. Primary Care Provider Education Project. Chronic Fatigue Syndrome: A Diagnostic and Management Challenge. Center for Disease Control and Prevention. 2003:3.
48. Felicetta J. Effects on illness on thyroid function tests. Postgraduate Medicine 1989;85(8):213-20.
49. Schimmel M, Utiger RD. Thyroidal and peripheral production of thyroid hormones: Review of recent findings and their clinical implications. Ann Intern Med 1977;87(6):760-68.
50. Refetoff S. Resistance to thyroid hormone: An historical overview. Thyroid 1994;4(3):345-49.
51. Bunevicius R, et al. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med 1999;340(6) 424-29.
52. Englebienne P, et al. Type I interferons induce proteins susceptible to act as thyroid receptor (TR) corepressors and to signal the TR for destruction by the proteasome: Possible etiology for unexplained chronic fatigue. Med Hypotheses 2003;60(2):175-80.
53.Garrison RL, Breeding PC. A metabolic basis for fibromyalgia and its related disorders: the possible role of resistance to thyroid hormone. Med Hypotheses 2003Aug; 61(2):182-89.
54. Primary Care Provider Education Project. Chronic Fatigue Syndrome: A Diagnostic and Management Challenge. Center for Disease Control and Prevention. 2003:3.
55. Refetoff S, Weiss RE, Usala SJ. The syndromes of resistance to thyroid hormone. Endocr Rev 1993;14(3):348-99.
56. Primary Care Provider Education Project. Chronic Fatigue Syndrome: A Diagnostic and Management Challenge. Center for Disease Control and Prevention. 2003:3.
57. Braverman LE, Utiger RD. Introduction to hypothyroidism. In: Werner and Ingbar’s The Thyroid: A Fundamental and Clinical Text. Baltimore, MD: Lippincott, 1991:919-920.
58. Scott LV, Svec F, Dinan T. A preliminary study of dehydroepiandrosterone response to low-dose ACTH in chronic fatigue syndrome and in healthy subjects. Psychiatry Res 2000;97(1): 21-8.
59. Primary Care Provider Education Project. Chronic Fatigue Syndrome: A Diagnostic and Management Challenge. Center for Disease Control and Prevention. 2003:3.
60. Iranmanish,A, et al. Dynamics of 24-hour endogenous cortisol secretion and clearance in primary hypothryoidsim assessed before and after partial thyroid hormone replacement. J.Clin.Endocrinol. Metab. 1990;70:155.
61. Gyulai L, et al. Bone mineral density in pre-and post-menopausal women with affective disorder treated with long-term L-thyroxine augmentation. J Affect Disord 2001:66(2-3):185-91.
62. Van Den Eeden SK, et al. Thyroid hormone use and the risk of hip fracture in women > or = 65 years: A case-control study. Journal of Women’s Health, 2003:12.
63. Sijanaovic S, Karaner I. Bone loss in premenopausal women on long term suppressive therapy with thyroid hormone. Medscape Women’s Health 2001.
64. Lowe JC, Reichman AJ, Yellin J. The process of change during T3 treatment for euthyroid fibromyalgia: A double-blind placebo-controlled crossover study. Clin. Bull. Myofascial Ther. 1997;2(2/3):91-124.
65. Wilson D. Personal communication. 2002;May 20.
